RAPID™ Imaging Platform Chosen for Patient Selection in TIMELESS Trial

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

iSchemaView today announced that the company’s RAPID imaging platform has been chosen for use in determining subject eligibility for the “Thrombolysis in imaging eligible late window patients (4.5-24 hours) to evaluate the efficacy and safety of tenecteplase,” TIMELESS trial, which will evaluate the efficacy and safety of tenecteplase compared with placebo in patients with late window acute ischemic stroke (AIS). Genentech, a member of the Roche Group, sponsored the study.

Stroke is the third leading cause of death and primary cause of long-term disability in the United States. Acute ischemic strokes (AIS) account for 87 percent of all strokes. An ischemic stroke occurs when an obstruction, like a blood clot, blocks blood flow to the brain.

The TIMELESS trial is designed to evaluate whether tenecteplase is safe and effective for use in AIS when administered between 4.5 and 24 hours after stroke onset.

“Advanced imaging with RAPID was instrumental in changing the AHA guidelines for thrombectomy (mechanical reperfusion) and has the potential to be equally impactful for thrombolysis (chemical reperfusion),” said Mikayel Grigoryan, M.D., Medical Director of Neurointervention at Adventist Health Glendale Comprehensive Stroke Center.

Unique in the comprehensive depth and range of its clinical validation, RAPID is now also the imaging standard in stroke research. iSchemaView’s imaging solution now has a research footprint across more than 300 stroke centers, more than 10 large-scale international clinical trials, and is being used clinically in over 800 hospitals worldwide. RAPID has been shown to aid in the selection of patients in early and late-window stroke trials, including SWIFT PRIME, EXTEND IA, DAWN, DEFUSE 3 and EXTEND, and has been granted FDA clearance for selection of patients for both early and late window thrombectomy.

“The choice of iSchemaView for the TIMELESS study makes it clear: RAPID is the de facto standard for clinical trials in stroke,” said Carolina Maier, PhD, Vice President of Research at iSchemaView. “RAPID is the only imaging technology for stroke that has been clinically validated, which is why it has been used in such a broad range of clinical trials and why it is used in over 1,000 stroke centers worldwide.”



Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.